The Experts below are selected from a list of 222 Experts worldwide ranked by ideXlab platform
Soren Friis - One of the best experts on this subject based on the ideXlab platform.
-
Hydrochlorothiazide use and risk for merkel cell carcinoma and malignant adnexal skin tumors a nationwide case control study
Journal of The American Academy of Dermatology, 2019Co-Authors: Anton Pottegard, Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David GaistAbstract:Background Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between Hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). Objective To examine the association between Hydrochlorothiazide use and the risk for MCC and MAST. Methods Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of Hydrochlorothiazide. Results The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of Hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as Hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0). Limitations No data on sun exposure was available. Conclusion Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.
-
Hydrochlorothiazide use and risk of nonmelanoma skin cancer a nationwide case control study from denmark
Journal of The American Academy of Dermatology, 2017Co-Authors: Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David Gaist, Anton PottegardAbstract:Background Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer. Objective To examine the association between Hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Methods From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative Hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with Hydrochlorothiazide use. Results High use of Hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between Hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC. Limitations No data on sun exposure were available. Conclusions Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC.
-
Hydrochlorothiazide use is strongly associated with risk of lip cancer
Journal of Internal Medicine, 2017Co-Authors: Anton Pottegard, Jesper Hallas, Morten Olesen, Mathias Tiedemann Svendsen, Laurel A Habel, Gary D Friedman, Soren FriisAbstract:SummaryBackground The diuretic Hydrochlorothiazide is among the most frequently prescribed drugs in the United States and Western Europe, but there is suggestive evidence that Hydrochlorothiazide use increases the risk of lip cancer. Objectives To study the association between use of Hydrochlorothiazide and squamous cell carcinoma of the lip. Methods We conducted a case–control study using Danish nationwide registry data. From the Cancer Registry (2004–2012), we identified 633 case patients with squamous cell carcinoma (SCC) of the lip and matched them to 63,067 population controls using a risk-set sampling strategy. Hydrochlorothiazide use (1995–2012) was obtained from the Prescription Registry and defined according to cumulative use. Applying conditional logistic regression, we calculated odds ratios (ORs) for SCC lip cancer associated with Hydrochlorothiazide use, adjusting for pre-defined potential confounders obtained from demographic, prescription, and patient registries. Results Ever-use of Hydrochlorothiazide was associated with an adjusted OR for SCC lip cancer of 2.1 (95% confidence interval (CI): 1.7–2.6), increasing to 3.9 (95%CI, 3.0–4.9) for high use (≥25,000 mg). There was a clear dose-response effect (p<0.001), with the highest cumulative dose category of Hydrochlorothiazide (≥100,000 mg) presenting an OR of 7.7 (95%CI: 5.7–10.5). No association with lip cancer was seen with use of other diuretics or non-diuretic antihypertensives. Assuming causality, we estimated that 11% of the SCC lip cancer cases could be attributed to Hydrochlorothiazide use. Conclusions Hydrochlorothiazide use is strongly associated with an increased risk of lip cancer. This article is protected by copyright. All rights reserved.
-
Hydrochlorothiazide use is strongly associated with risk of lip cancer
Journal of Internal Medicine, 2017Co-Authors: Anton Pottegard, Jesper Hallas, Morten Olesen, Mathias Tiedemann Svendsen, Laurel A Habel, Gary D Friedman, Soren FriisAbstract:SummaryBackground The diuretic Hydrochlorothiazide is among the most frequently prescribed drugs in the United States and Western Europe, but there is suggestive evidence that Hydrochlorothiazide use increases the risk of lip cancer. Objectives To study the association between use of Hydrochlorothiazide and squamous cell carcinoma of the lip. Methods We conducted a case–control study using Danish nationwide registry data. From the Cancer Registry (2004–2012), we identified 633 case patients with squamous cell carcinoma (SCC) of the lip and matched them to 63,067 population controls using a risk-set sampling strategy. Hydrochlorothiazide use (1995–2012) was obtained from the Prescription Registry and defined according to cumulative use. Applying conditional logistic regression, we calculated odds ratios (ORs) for SCC lip cancer associated with Hydrochlorothiazide use, adjusting for pre-defined potential confounders obtained from demographic, prescription, and patient registries. Results Ever-use of Hydrochlorothiazide was associated with an adjusted OR for SCC lip cancer of 2.1 (95% confidence interval (CI): 1.7–2.6), increasing to 3.9 (95%CI, 3.0–4.9) for high use (≥25,000 mg). There was a clear dose-response effect (p
Anton Pottegard - One of the best experts on this subject based on the ideXlab platform.
-
Hydrochlorothiazide use and risk for merkel cell carcinoma and malignant adnexal skin tumors a nationwide case control study
Journal of The American Academy of Dermatology, 2019Co-Authors: Anton Pottegard, Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David GaistAbstract:Background Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between Hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). Objective To examine the association between Hydrochlorothiazide use and the risk for MCC and MAST. Methods Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of Hydrochlorothiazide. Results The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of Hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as Hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0). Limitations No data on sun exposure was available. Conclusion Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.
-
Hydrochlorothiazide use and risk of nonmelanoma skin cancer a nationwide case control study from denmark
Journal of The American Academy of Dermatology, 2017Co-Authors: Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David Gaist, Anton PottegardAbstract:Background Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer. Objective To examine the association between Hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Methods From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative Hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with Hydrochlorothiazide use. Results High use of Hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between Hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC. Limitations No data on sun exposure were available. Conclusions Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC.
-
Hydrochlorothiazide use is strongly associated with risk of lip cancer
Journal of Internal Medicine, 2017Co-Authors: Anton Pottegard, Jesper Hallas, Morten Olesen, Mathias Tiedemann Svendsen, Laurel A Habel, Gary D Friedman, Soren FriisAbstract:SummaryBackground The diuretic Hydrochlorothiazide is among the most frequently prescribed drugs in the United States and Western Europe, but there is suggestive evidence that Hydrochlorothiazide use increases the risk of lip cancer. Objectives To study the association between use of Hydrochlorothiazide and squamous cell carcinoma of the lip. Methods We conducted a case–control study using Danish nationwide registry data. From the Cancer Registry (2004–2012), we identified 633 case patients with squamous cell carcinoma (SCC) of the lip and matched them to 63,067 population controls using a risk-set sampling strategy. Hydrochlorothiazide use (1995–2012) was obtained from the Prescription Registry and defined according to cumulative use. Applying conditional logistic regression, we calculated odds ratios (ORs) for SCC lip cancer associated with Hydrochlorothiazide use, adjusting for pre-defined potential confounders obtained from demographic, prescription, and patient registries. Results Ever-use of Hydrochlorothiazide was associated with an adjusted OR for SCC lip cancer of 2.1 (95% confidence interval (CI): 1.7–2.6), increasing to 3.9 (95%CI, 3.0–4.9) for high use (≥25,000 mg). There was a clear dose-response effect (p<0.001), with the highest cumulative dose category of Hydrochlorothiazide (≥100,000 mg) presenting an OR of 7.7 (95%CI: 5.7–10.5). No association with lip cancer was seen with use of other diuretics or non-diuretic antihypertensives. Assuming causality, we estimated that 11% of the SCC lip cancer cases could be attributed to Hydrochlorothiazide use. Conclusions Hydrochlorothiazide use is strongly associated with an increased risk of lip cancer. This article is protected by copyright. All rights reserved.
-
Hydrochlorothiazide use is strongly associated with risk of lip cancer
Journal of Internal Medicine, 2017Co-Authors: Anton Pottegard, Jesper Hallas, Morten Olesen, Mathias Tiedemann Svendsen, Laurel A Habel, Gary D Friedman, Soren FriisAbstract:SummaryBackground The diuretic Hydrochlorothiazide is among the most frequently prescribed drugs in the United States and Western Europe, but there is suggestive evidence that Hydrochlorothiazide use increases the risk of lip cancer. Objectives To study the association between use of Hydrochlorothiazide and squamous cell carcinoma of the lip. Methods We conducted a case–control study using Danish nationwide registry data. From the Cancer Registry (2004–2012), we identified 633 case patients with squamous cell carcinoma (SCC) of the lip and matched them to 63,067 population controls using a risk-set sampling strategy. Hydrochlorothiazide use (1995–2012) was obtained from the Prescription Registry and defined according to cumulative use. Applying conditional logistic regression, we calculated odds ratios (ORs) for SCC lip cancer associated with Hydrochlorothiazide use, adjusting for pre-defined potential confounders obtained from demographic, prescription, and patient registries. Results Ever-use of Hydrochlorothiazide was associated with an adjusted OR for SCC lip cancer of 2.1 (95% confidence interval (CI): 1.7–2.6), increasing to 3.9 (95%CI, 3.0–4.9) for high use (≥25,000 mg). There was a clear dose-response effect (p
Sidsel Arnspang Pedersen - One of the best experts on this subject based on the ideXlab platform.
-
Hydrochlorothiazide use and risk for merkel cell carcinoma and malignant adnexal skin tumors a nationwide case control study
Journal of The American Academy of Dermatology, 2019Co-Authors: Anton Pottegard, Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David GaistAbstract:Background Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between Hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). Objective To examine the association between Hydrochlorothiazide use and the risk for MCC and MAST. Methods Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of Hydrochlorothiazide. Results The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of Hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as Hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0). Limitations No data on sun exposure was available. Conclusion Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.
-
Hydrochlorothiazide use and risk of nonmelanoma skin cancer a nationwide case control study from denmark
Journal of The American Academy of Dermatology, 2017Co-Authors: Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David Gaist, Anton PottegardAbstract:Background Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer. Objective To examine the association between Hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Methods From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative Hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with Hydrochlorothiazide use. Results High use of Hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between Hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC. Limitations No data on sun exposure were available. Conclusions Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC.
David Gaist - One of the best experts on this subject based on the ideXlab platform.
-
Hydrochlorothiazide use and risk for merkel cell carcinoma and malignant adnexal skin tumors a nationwide case control study
Journal of The American Academy of Dermatology, 2019Co-Authors: Anton Pottegard, Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David GaistAbstract:Background Hydrochlorothiazide use has been associated with markedly increased risk for squamous cell carcinoma. No previous studies have investigated the association between Hydrochlorothiazide use and the risk for Merkel cell carcinoma (MCC) and malignant adnexal skin tumors (MAST). Objective To examine the association between Hydrochlorothiazide use and the risk for MCC and MAST. Methods Using Danish nationwide health registries, we identified all patients with incident MCC or MAST during 2004-2015 and matched the cases individually to cancer-free population controls by risk set sampling. Using conditional logistic regression, we estimated the odds ratios (ORs) and confidence intervals (CIs) associated with cumulative use of Hydrochlorothiazide. Results The adjusted ORs for MCC and MAST associated with high use (≥50,000 mg) of Hydrochlorothiazide was 2.3 (95% CI 1.1-4.8) and 3.6 (95% CI 1.9-7.0), respectively, which increased to 3.3 (95% CI 1.3-8.3) and 5.6 (95% CI 2.4-13.3), respectively, with highest use (≥100,000 mg). We found no increased risk for these tumors in analyses of drugs with similar indications as Hydrochlorothiazide, except there was a tendency toward an increased risk for MCC associated with the use of furosemide (OR 1.9, 95% CI 0.9-4.0). Limitations No data on sun exposure was available. Conclusion Hydrochlorothiazide use is associated with an increased risk for MCC and MAST.
-
Hydrochlorothiazide use and risk of nonmelanoma skin cancer a nationwide case control study from denmark
Journal of The American Academy of Dermatology, 2017Co-Authors: Soren Friis, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Lisbet Rosenkrantz Holmich, David Gaist, Anton PottegardAbstract:Background Hydrochlorothiazide, one of the most frequently used diuretic and antihypertensive drugs in the United States and Western Europe, is photosensitizing and has previously been linked to lip cancer. Objective To examine the association between Hydrochlorothiazide use and the risk of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Methods From the Danish Cancer Registry, we identified patients (cases) with nonmelanoma skin cancer (NMSC) during 2004-2012. Controls were matched 1:20 by age and sex. Cumulative Hydrochlorothiazide use (in 1995-2012) was assessed from the Danish Prescription Registry. Using conditional logistic regression, we calculated odds ratios (ORs) for BCC and SCC associated with Hydrochlorothiazide use. Results High use of Hydrochlorothiazide (≥50,000 mg) was associated with ORs of 1.29 (95% confidence interval [CI], 1.23-1.35) for BCC and 3.98 (95% CI, 3.68-4.31) for SCC. We found clear dose-response relationships between Hydrochlorothiazide use and both BCC and SCC; the highest cumulative dose category (≥200,000 mg of HCTZ) had ORs of 1.54 (95% CI, 1.38-1.71) and 7.38 (95% CI, 6.32-8.60) for BCC and SCC, respectively. Use of other diuretics and antihypertensives was not associated with NMSC. Limitations No data on sun exposure were available. Conclusions Hydrochlorothiazide use is associated with a substantially increased risk of NMSC, especially SCC.
Syed M. Mohiuddin - One of the best experts on this subject based on the ideXlab platform.
-
Valsartan/Hydrochlorothiazide: pharmacology and clinical efficacy
Expert opinion on drug metabolism & toxicology, 2009Co-Authors: Robyn Kondrack, Syed M. MohiuddinAbstract:Background: Valsartan/Hydrochlorothiazide is a combination of an angiotensin II receptor antagonist and diuretic indicated for hypertensive patients as initial therapy and those not controlled on monotherapy. Objective: To evaluate the pharmacokinetic, pharmacodynamic and clinical efficacy of valsartan/Hydrochlorothiazide in hypertension therapy and other cardiovascular outcomes. Methods: Review of current literature. Results: Valsartan/Hydrochlorothiazide has been shown to be superior to its individual components in randomized controlled studies of patients with moderate-to-severe hypertension and in patients who did not respond to monotherapy. When compared to amlodipine, valsartan/Hydrochlorothiazide was shown to have a similar rate of the combined outcome of morbidity and mortality. Valsartan/Hydrochlorothiazide has also been studied in specific patient populations, such as diabetics, obese, elderly, black hypertensives and hypertensives with further cardiovascular risk factors, and has been shown to ...
